Targets › HTR3A
14 programs from 14 companies in 19 trials: 8 Phase 2, 6 Phase 4, 4 Phase 3, 1 Phase 1; Oncology, Other, Genitourinary; next expected readout Dec 2026.
Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons. (UniProt, P46098)
Open in Phaseline: the race on HTR3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai 6th People's Hospital | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 4 | Chemotherapy-induced Nausea and Vomiting | Dec 2026 |
| Sanliurfa Education and Research Hospital | metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 4 | Intraoperative Nausea-retching-vomiting Episodes | Jan 2027 |
| Heron Therapeutics | Granisetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 4 | Chemotherapy-Induced Nausea and Vomiting (CINV); TMD; Nausea With Vomiting Chemotherapy-Induced; Nephrotoxicity | – |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 4 | Endometrial Cancer | – |
| University of Colorado, Denver | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 3 | Nephrotoxicity | Sep 2027 |
| Affiliated Hospital of Qinghai University | Metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 3 | Nausea | Dec 2027 |
| Takeda | Vortioxetine Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist | HTR1A, SLC6A4, HTR3A | Phase 3 | Major Depressive Disorder; Glioblastoma; Depression | Sep 2029 |
| Seoul National University Hospital | Ramosetron Serotonin 3 (5-HT3) receptor antagonist | HTR3A, HTR3E, HTR3B, HTR3D, HTR3C | Phase 2 | Fecal Incontinence | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 2 | Esophagus Cancer | Jan 2027 |
| Simon Fisher | Metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 2 | Hypoglycemia Unawareness | Jun 2027 |
| Mahidol University | palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 2 | Cancer (Solid Tumors) | Oct 2027 |
| Chinese University of Hong Kong | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 2 | Breast Cancer | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 2 | Solid Tumor Cancer | Jan 2028 |
| Tianjin Medical University Cancer Institute and Hospital | Palonosetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 2 | Chemotherapy-Induced Nausea and Vomiting (CINV) | Jun 2028 |
Nephrotoxicity (2) Chemotherapy-Induced Nausea and Vomiting (CINV) (2) TMD (1) Nausea With Vomiting Chemotherapy-Induced (1) Solid Tumor Cancer (1) Major Depressive Disorder (1) Glioblastoma (1) Depression (1) Endometrial Cancer (1) Breast Cancer (1) Cancer (Solid Tumors) (1) Chemotherapy-induced Nausea and Vomiting (1)
small molecule (13), protein or peptide (1)
University of Colorado, Denver (1) Tianjin Medical University Cancer Institute and Hospital (1) Heron Therapeutics (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Takeda (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) Chinese University of Hong Kong (1) Mahidol University (1) Shanghai 6th People's Hospital (1) Affiliated Hospital of Qinghai University (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Sanliurfa Education and Research Hospital (1) Simon Fisher (1) Seoul National University Hospital (1)
DRD2 (3) HTR4 (3) HTR1A (1) SLC6A4 (1) HTR3E (1) HTR3B (1) HTR3D (1) HTR3C (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.